CG Oncology (CGON) Payables (2023 - 2026)

CG Oncology has reported Payables for 4 years, with the latest figure at $8.2 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 22.36% year-over-year to $8.2 million; the trailing twelve-month figure through Mar 2026 stood at $8.2 million (up 22.36% YoY), and the FY2025 full-year result was $5.7 million, down 12.32% from the prior year.
• Payables for Q1 2026 stood at $8.2 million, up from $5.7 million in the prior quarter.
• The five-year high for Payables was $11.3 million in Q3 2024, with the low at $3.2 million in Q4 2023.
• Historically, Payables has averaged $7.0 million across 4 years, with a median of $6.9 million in 2024.
• Annual changes were most pronounced in 2024 — Payables jumped 101.02% — and 2025, when it slipped 18.85%.
• CG Oncology's Payables stood at $3.2 million in 2023, then jumped by 101.02% to $6.5 million in 2024, then fell by 12.32% to $5.7 million in 2025, then jumped by 44.14% to $8.2 million in 2026.
• The last three Payables figures came in at $8.2 million (Q1 2026), $5.7 million (Q4 2025), and $9.2 million (Q3 2025), per Business Quant data.